http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2019008643-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23d6930caa349da7faa9ff5254094423
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-04
filingDate 2015-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1b0b1d94e64311bb3ac65aa3c5f8751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6a6e2e4ac64cb8eb28a54f326b4406c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a8a2663a94f81063e7c03cbf9854801
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85ea70f93e0328f9ceacba1e3a787d10
publicationDate 2019-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-2019008643-A
titleOfInvention USE OF SERLOPITANT AS ANTAGONISTS OF THE NK-1 RECEPTOR IN PRURITO.
abstract The present invention relates to methods of treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. Furthermore, the invention encompasses the treatment of a condition associated with pruritus with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep aid agent.
priorityDate 2013-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23653789
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426257199

Total number of triples: 28.